COVID-19 mRNA vaccine in patients with lymphoid malignancy or anti-CD20 antibody therapy: a systematic review and meta-analysis
Y Ito, A Honda, M Kurokawa - Clinical Lymphoma Myeloma and Leukemia, 2022 - Elsevier
Background The humoral response to vaccination in individuals with lymphoid malignancies
or those undergoing anti-CD20 antibody therapy is impaired, but details of the response to …
or those undergoing anti-CD20 antibody therapy is impaired, but details of the response to …
[PDF][PDF] Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer
Little is known on the long-lasting humoral response and the T cell activation induced by
SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the …
SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the …